Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
NCT ID: NCT06203704
Last Updated: 2025-10-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
1086 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-12-20
Study Completion Date
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The OPTIMISE-CKD CEE study design will create a real-world evidence platform that systematically leverages the routine data collection made by Investigators and will help obtain relevant insights from clinical practice. This study is likely to include a more heterogeneous population compared with the constraints required by interventional study protocols. Treatment decisions, clinical outcomes, and common treatment scenarios in the context of routine care of CKD are likely to be more generalizable than those from clinical trials.
It is important to assess the current CKD treatment with dapagliflozin. The research questions can be divided into two categories:
1. What does the dapagliflozin utilisation in CKD look like?
a. Who are being treated?
2. What are the selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin, with or without type 2 diabetes (T2D) up to 12 months post-initiation?
Primary objective is to characterize dapagliflozin utilisation in clinical practice, by describing treatment naïve patients who are treated with dapagliflozin for CKD.
Secondary objectives are to describe selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin up to 12 months post-initiation.
The OPTIMISE-CKD CEE study is a multinational, observational, longitudinal cohort study, with a pre-post design, which will include patients who are treated with dapagliflozin with CKD in real-world clinical practice, utilising secondary data sources. This is a secondary data collection study, where variables are extracted from electronic or paper medical records.
Seven Central Eastern Europe countries are planned to participate in the study: Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia. A total number of 1090 patients are estimated to be included in the study.
The study population will consist of adult patients with CKD who meet the country-specific label for dapagliflozin as treatment for CKD across CEE.
It is important to assess the current CKD treatment with dapagliflozin. The research questions can be divided into two categories:
1. What does the dapagliflozin utilisation in CKD look like?
a. Who are being treated?
2. What are the selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin, with or without type 2 diabetes (T2D) up to 12 months post-initiation?
Primary objective is to characterize dapagliflozin utilisation in clinical practice, by describing treatment naïve patients who are treated with dapagliflozin for CKD.
Secondary objectives are to describe selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin up to 12 months post-initiation.
The OPTIMISE-CKD CEE study is a multinational, observational, longitudinal cohort study, with a pre-post design, which will include patients who are treated with dapagliflozin with CKD in real-world clinical practice, utilising secondary data sources. This is a secondary data collection study, where variables are extracted from electronic or paper medical records.
Seven Central Eastern Europe countries are planned to participate in the study: Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia. A total number of 1090 patients are estimated to be included in the study.
The study population will consist of adult patients with CKD who meet the country-specific label for dapagliflozin as treatment for CKD across CEE.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OPTIMISE-CKD Drug Utilization
NCT05932901
Chronic Kidney Disease
COMPLETED
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
NCT03036150
Chronic Kidney Disease
COMPLETED
PHASE3
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526
Chronic Kidney Disease
RECRUITING
PHASE4
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291
Kidney Disease, Chronic
Renal Transplant Failure
Heart Failure
+2 more
ENROLLING_BY_INVITATION
PHASE3
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
NCT05196347
Chronic Kidney Diseases
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The OPTIMISE-CKD CEE study design will create a real-world evidence platform that systematically leverages the routine data collection made by Investigators and will help obtain relevant insights from clinical practice. This study is likely to include a more heterogeneous population compared with the constraints required by interventional study protocols. Treatment decisions, clinical outcomes, and common treatment scenarios in the context of routine care of CKD are likely to be more generalizable than those from clinical trials. The results of the study will be used to better inform the medical community, and decision-makers about current and future needs in the CKD management in CEE in real-life setting. The approved label encompasses all CKD patients at risk of disease progression and is thereby broader than the DAPA-CKD trial population. It is important for physicians and patients to better understand dapagliflozin use in CKD in routine clinical practice, particularly among patients who might have been underrepresented in clinical trials. Additionally, payers require additional evidence from the broader CKD population prior to making reimbursement recommendations that will enable access for all patients who have the approved CKD indication.
It is important to assess the current CKD treatment with dapagliflozin. Primary objective is to characterize dapagliflozin utilisation in clinical practice, by describing treatment naïve patients who are treated with dapagliflozin for CKD.
To describe characteristics among patients newly initiated on dapagliflozin 10 mg for CKD, the following will be used:
1. Baseline demographics and clinical characteristics
2. Baseline laboratory measures
3. Baseline concomitant medications, by drug class and specific drugs of interest.
Secondary objectives are to describe selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin up to 12 months post-initiation:
1. CKD progression (advancement in CKD stage)
2. Selected clinical outcomes: cardio-renal events (e.g., CKD progression, HF, nonfatal stroke, nonfatal MI)
3. Selected healthcare resource utilization, e.g., all-cause hospitalizations, cardio-renal hospitalizations (CKD, hHF, MACE \[nonfatal stroke, nonfatal MI\])
4. Treatment patterns of dapagliflozin, RAASi (ACE inhibitors / ARB), and other selected medications used for CVD and T2D, defined as time to discontinuation (dapagliflozin only), medication additions, discontinuations, and dosage changes.
Study design: The OPTMISE-CKD CEE regional study is an observational, longitudinal cohort study with a pre-post design, which will include patients who are treated with dapagliflozin for CKD in real-world clinical practice, utilising secondary data sources in 7 countries (Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia) from CEE. The data extraction from medical charts will be made by Investigators, only after eligible patients express their written consent for data collection in the OPTIMISE-CKD study during the enrolment period defined at study level. A period of min. 30 days and max. 90 days after dapagliflozin was initiated is required for enrolment. Given the secondary data collection character of this study, no study-specific diagnostic and monitoring processes are to be applied to the patients.
Data Sources: Disease and treatment-related information routinely collected in clinical practice will be extracted by Investigators from paper and/or electronic health records (EHR). Data from all participating centers will be collected into a single anonymized dataset for analysis, by means of electronic case report forms (CRFs).
Study Population: Adult patients (aged ≥18 years) with CKD who initiated dapagliflozin 10 mg and meet all inclusion criteria and none of the exclusion criteria. Enrolment is to be performed minimum 30 days and maximum 90 days since initiation of dapagliflozin for CKD. Previous treatment with dapagliflozin or SGLT-2i deems patient ineligibility.
Exposure(s): The study will describe CKD treatments and drug utilisation patterns (Section 4.2), specifically for dapagliflozin 10 mg, RAASi and other treatments routinely used in the management of CKD patients (see Section 4.4) up to 12 months post-dapagliflozin initiation. Data on exposure to dapagliflozin, RAASi, and other CKD/CVD/T2D-related treatments prescribed as part of routine care will be collected. In all cases, the decision to treat a patient with dapagliflozin will be made prior to the decision to enroll a patient into the study. All treatment decisions are at the discretion of the current patient's physician, based on clinical judgment and recommendations included in the approved label and national treatment protocols, and are not mandated by this protocol.
Study measures:
* Baseline demographic, clinical characteristics, comorbidities and medications
* Post-index medications (changes, including addition, and discontinuation, and time to discontinuation for dapagliflozin)
* Post-index cardio-renal events
* Post-index healthcare resource use Sample Size Estimations: This study does not involve hypothesis testing. No formal sample size and power calculations have been performed. Across participating CEE countries (Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia), an estimated number of 1090 patients is planned for inclusion, with country target numbers varying between 70 and 300 patients, depending on preliminary feasibility with sites, the size of the country and reimbursement status at study start and during the study. The target number of patients is planned to be enrolled in 6-8 months across the region. If this target sample is not reached, this does not imply study failure, but the precision on estimates will change.
Statistical Analysis: The statistical analyses will be fully described in the Statistical Analysis Plan (SAP) as appropriate. Descriptive analyses will be performed to describe the characteristics of the cohort studied. Continuous variables will be summarized using means with standard deviations (SDs), medians with interquartile ranges (IQR), and minimum and maximum values. The number and percentages of patients will be used to summarize categorical variables, including a separate category for patients with missing data at baseline. Missing data will be quantified for all study variables, but there will be no attempts to impute them. For the secondary objective, the time to discontinuation will be estimated using the Kaplan-Meier method. Summary statistics will be used to describe proportions of patients with the event changes within the set time windows.
Baseline demographic and clinical characteristics will be summarized on the index date. For laboratory data, the value closest to index (in the last year before or on the index date) will be used. Comorbidities and medical history will be summarized in the last year before index date. Stratified analyses based on baseline demographic and clinical characteristics may be performed.
Summary statistics will be used to describe treatment patterns and drug utilisation. Further specification on planned analyses will be provided in the SAP
It is important to assess the current CKD treatment with dapagliflozin. Primary objective is to characterize dapagliflozin utilisation in clinical practice, by describing treatment naïve patients who are treated with dapagliflozin for CKD.
To describe characteristics among patients newly initiated on dapagliflozin 10 mg for CKD, the following will be used:
1. Baseline demographics and clinical characteristics
2. Baseline laboratory measures
3. Baseline concomitant medications, by drug class and specific drugs of interest.
Secondary objectives are to describe selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin up to 12 months post-initiation:
1. CKD progression (advancement in CKD stage)
2. Selected clinical outcomes: cardio-renal events (e.g., CKD progression, HF, nonfatal stroke, nonfatal MI)
3. Selected healthcare resource utilization, e.g., all-cause hospitalizations, cardio-renal hospitalizations (CKD, hHF, MACE \[nonfatal stroke, nonfatal MI\])
4. Treatment patterns of dapagliflozin, RAASi (ACE inhibitors / ARB), and other selected medications used for CVD and T2D, defined as time to discontinuation (dapagliflozin only), medication additions, discontinuations, and dosage changes.
Study design: The OPTMISE-CKD CEE regional study is an observational, longitudinal cohort study with a pre-post design, which will include patients who are treated with dapagliflozin for CKD in real-world clinical practice, utilising secondary data sources in 7 countries (Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia) from CEE. The data extraction from medical charts will be made by Investigators, only after eligible patients express their written consent for data collection in the OPTIMISE-CKD study during the enrolment period defined at study level. A period of min. 30 days and max. 90 days after dapagliflozin was initiated is required for enrolment. Given the secondary data collection character of this study, no study-specific diagnostic and monitoring processes are to be applied to the patients.
Data Sources: Disease and treatment-related information routinely collected in clinical practice will be extracted by Investigators from paper and/or electronic health records (EHR). Data from all participating centers will be collected into a single anonymized dataset for analysis, by means of electronic case report forms (CRFs).
Study Population: Adult patients (aged ≥18 years) with CKD who initiated dapagliflozin 10 mg and meet all inclusion criteria and none of the exclusion criteria. Enrolment is to be performed minimum 30 days and maximum 90 days since initiation of dapagliflozin for CKD. Previous treatment with dapagliflozin or SGLT-2i deems patient ineligibility.
Exposure(s): The study will describe CKD treatments and drug utilisation patterns (Section 4.2), specifically for dapagliflozin 10 mg, RAASi and other treatments routinely used in the management of CKD patients (see Section 4.4) up to 12 months post-dapagliflozin initiation. Data on exposure to dapagliflozin, RAASi, and other CKD/CVD/T2D-related treatments prescribed as part of routine care will be collected. In all cases, the decision to treat a patient with dapagliflozin will be made prior to the decision to enroll a patient into the study. All treatment decisions are at the discretion of the current patient's physician, based on clinical judgment and recommendations included in the approved label and national treatment protocols, and are not mandated by this protocol.
Study measures:
* Baseline demographic, clinical characteristics, comorbidities and medications
* Post-index medications (changes, including addition, and discontinuation, and time to discontinuation for dapagliflozin)
* Post-index cardio-renal events
* Post-index healthcare resource use Sample Size Estimations: This study does not involve hypothesis testing. No formal sample size and power calculations have been performed. Across participating CEE countries (Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia), an estimated number of 1090 patients is planned for inclusion, with country target numbers varying between 70 and 300 patients, depending on preliminary feasibility with sites, the size of the country and reimbursement status at study start and during the study. The target number of patients is planned to be enrolled in 6-8 months across the region. If this target sample is not reached, this does not imply study failure, but the precision on estimates will change.
Statistical Analysis: The statistical analyses will be fully described in the Statistical Analysis Plan (SAP) as appropriate. Descriptive analyses will be performed to describe the characteristics of the cohort studied. Continuous variables will be summarized using means with standard deviations (SDs), medians with interquartile ranges (IQR), and minimum and maximum values. The number and percentages of patients will be used to summarize categorical variables, including a separate category for patients with missing data at baseline. Missing data will be quantified for all study variables, but there will be no attempts to impute them. For the secondary objective, the time to discontinuation will be estimated using the Kaplan-Meier method. Summary statistics will be used to describe proportions of patients with the event changes within the set time windows.
Baseline demographic and clinical characteristics will be summarized on the index date. For laboratory data, the value closest to index (in the last year before or on the index date) will be used. Comorbidities and medical history will be summarized in the last year before index date. Stratified analyses based on baseline demographic and clinical characteristics may be performed.
Summary statistics will be used to describe treatment patterns and drug utilisation. Further specification on planned analyses will be provided in the SAP
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Kidney Disease (CKD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adult patients (age ≥18 years) at the time of dapagliflozin start
2. Patient receives treatment with dapagliflozin for CKD in accordance with the dapagliflozin product label and local dapagliflozin reimbursement criteria for CKD
Note: CKD diagnosis is based on the following KDIGO criteria \[KDIGO 2012\] that defines CKD as abnormalities of kidney structure or function, present for \>3 months, with implications for health and at least one of the following criteria:
* AER ≥30 mg/24 hours;
* ACR ≥30 mg/g (≥3 mg/mmol);
* eGFR \<60 ml/min/1.73 m2.
3. Signed and dated informed consent prior to enrollment in the study.
2. Patient receives treatment with dapagliflozin for CKD in accordance with the dapagliflozin product label and local dapagliflozin reimbursement criteria for CKD
Note: CKD diagnosis is based on the following KDIGO criteria \[KDIGO 2012\] that defines CKD as abnormalities of kidney structure or function, present for \>3 months, with implications for health and at least one of the following criteria:
* AER ≥30 mg/24 hours;
* ACR ≥30 mg/g (≥3 mg/mmol);
* eGFR \<60 ml/min/1.73 m2.
3. Signed and dated informed consent prior to enrollment in the study.
Exclusion Criteria
1. Diagnosed with type 1 diabetes \[ICD-10 codes E10 and O24.0\] at any time before index date.
2. Diagnosed with gestational diabetes mellitus \[ICD-10 code O24.419\] at any time before index date.
3. Patient is enrolled less than 30 days or more than 90 days, following initiation of dapagliflozin.
4. Prior treatment (at any time before index date) with dapagliflozin or other SGLT-2i
5. Enrolment in a clinical trial that includes specific treatments as investigational medicinal product on or 3 months before index date
6. Renal transplant at any time before index date
7. End stage renal disease (eGFR \<15 ml/min/1.73m2) on index date
8. Chronic dialysis on or at any time before index date
2. Diagnosed with gestational diabetes mellitus \[ICD-10 code O24.419\] at any time before index date.
3. Patient is enrolled less than 30 days or more than 90 days, following initiation of dapagliflozin.
4. Prior treatment (at any time before index date) with dapagliflozin or other SGLT-2i
5. Enrolment in a clinical trial that includes specific treatments as investigational medicinal product on or 3 months before index date
6. Renal transplant at any time before index date
7. End stage renal disease (eGFR \<15 ml/min/1.73m2) on index date
8. Chronic dialysis on or at any time before index date
Minimum Eligible Age
18 Years
Maximum Eligible Age
130 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Plovdiv, , Bulgaria
Site Status
Research Site
Sofia, , Bulgaria
Site Status
Research Site
Varna, , Bulgaria
Site Status
Research Site
Zagreb, , Croatia
Site Status
Research Site
Békéscsaba, , Hungary
Site Status
Research Site
Budapest, , Hungary
Site Status
Research Site
Debrecen, , Hungary
Site Status
Research Site
Gödöllő, , Hungary
Site Status
Research Site
Karcag, , Hungary
Site Status
Research Site
Kecskemét, , Hungary
Site Status
Research Site
Miskolc, , Hungary
Site Status
Research Site
Nagykanizsa, , Hungary
Site Status
Research Site
Nyíregyháza, , Hungary
Site Status
Research Site
Pécs, , Hungary
Site Status
Research Site
Siófok, , Hungary
Site Status
Research Site
Szeged, , Hungary
Site Status
Research Site
Szombathely, , Hungary
Site Status
Research Site
Veszprém, , Hungary
Site Status
Research Site
Bialystok, , Poland
Site Status
Research Site
Bolesławiec, , Poland
Site Status
Research Site
Bydgoszcz, , Poland
Site Status
Research Site
Choszczno, , Poland
Site Status
Research Site
Czarnków, , Poland
Site Status
Research Site
Katowice, , Poland
Site Status
Research Site
Krakow, , Poland
Site Status
Research Site
Lodz, , Poland
Site Status
Research Site
Olsztyn, , Poland
Site Status
Research Site
Opole, , Poland
Site Status
Research Site
Sieradz, , Poland
Site Status
Research Site
Szczecin, , Poland
Site Status
Research Site
Środa Wielkopolska, , Poland
Site Status
Research Site
Węgrów, , Poland
Site Status
Research Site
Wroclaw, , Poland
Site Status
Research Site
Zielona Góra, , Poland
Site Status
Research Site
Żywiec, , Poland
Site Status
Research Site
Bistriţa, , Romania
Site Status
Research Site
Bucharest, , Romania
Site Status
Research Site
Cluj-Napoca, , Romania
Site Status
Research Site
Galati, , Romania
Site Status
Research Site
Iași, , Romania
Site Status
Research Site
Oradea, , Romania
Site Status
Research Site
Reşiţa, , Romania
Site Status
Research Site
Satu Mare, , Romania
Site Status
Research Site
Târgu Mureş, , Romania
Site Status
Research Site
Timișoara, , Romania
Site Status
Research Site
Belgrade, , Serbia
Site Status
Research Site
Brežice, , Slovenia
Site Status
Research Site
Cerknica, , Slovenia
Site Status
Research Site
Mengeš, , Slovenia
Site Status
Research Site
Portorož, , Slovenia
Site Status
Research Site
Ptuj, , Slovenia
Site Status
Research Site
Radlje ob Dravi, , Slovenia
Site Status
Research Site
Ruše, , Slovenia
Site Status
Research Site
Sevnica, , Slovenia
Site Status
Research Site
Škofja Loka, , Slovenia
Site Status
Research Site
Zagorje, , Slovenia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Bulgaria
Croatia
Hungary
Poland
Romania
Serbia
Slovenia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D169AR00025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
NCT04930549
UNKNOWN
PHASE2
Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
NCT06560801
RECRUITING
PHASE4
Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
NCT06281899
RECRUITING
PHASE4
Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
NCT05713851
RECRUITING
PHASE2/PHASE3
Dapagliflozin in Non-diabetic Stage IV CKD
NCT04794517
COMPLETED
PHASE2
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398
COMPLETED
PHASE3
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260
COMPLETED
PHASE2/PHASE3
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT06651021
COMPLETED
PHASE1
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495
COMPLETED
PHASE2
Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
NCT03190694
COMPLETED
PHASE2
Study With Dapagliflozin
NCT02971618
COMPLETED
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
NCT05306210
COMPLETED
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
NCT03152084
TERMINATED
PHASE4
Dapagliflozin Post Marketing Surveillance in HF and CKD
NCT05134701
COMPLETED
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
ACTIVE_NOT_RECRUITING
PHASE3
A Phase 2b Diabetic Kidney Disease Study
NCT04170543
COMPLETED
PHASE2
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
NCT06982079
RECRUITING
PHASE3
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714
RECRUITING
PHASE1/PHASE2
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
NCT05225077
UNKNOWN
PHASE4
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570
RECRUITING
PHASE4
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
NCT02695082
COMPLETED
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585
RECRUITING
PHASE3
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
NCT06942910
RECRUITING
PHASE2
A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose
NCT01072578
COMPLETED
PHASE1
Olmesartan Medoxomil and Diabetic Nephropathy
NCT00362960
COMPLETED
PHASE3